Psilocybin
Health Canada Releases Guidelines for Psychedelic Therapy
The article Health Canada Releases Guidelines for Psychedelic Therapy was originally published on Microdose.
Health Canada has released a Notice to…
The article Health Canada Releases Guidelines for Psychedelic Therapy was originally published on Microdose.
Health Canada has released a Notice to Stakeholders, outlining its expectations regarding risk-management measures for clinical trials involving psychedelic-assisted psychotherapy.
Despite mixed-messaging from Health Canada regarding their support for psychedelic therapy, the arc seems to be bending in the direction of a future of government-supported access. This notice shows that the agency is acknowledging that psychedelic therapy will be a reality going forward, and is thus doing its bureaucratic duties and getting stuff down in writing as to expectations and standards of practice.
From their introduction:
Health Canada recognizes the growing interest in the use of psychedelic-assisted psychotherapy and of the possible psychological and physical risks to clinical trial participants associated with this type of therapy. Because of these risks, Health Canada is publishing this notice to outline its expectations regarding the implementation of risk-management measures by clinical trial sponsors. Although there are no established clinical practice guidelines for psychedelic-assisted psychotherapy, some best practices are emerging in the literature. This document is intended to reflect these best practices.
The notice is broken down into sections, including:
- Risk-management measures for CTAs involving psychedelic-assisted psychotherapy
- Expectations regarding therapists and clinical setting
- Good manufacturing practices (GMP)
This isn’t headline-grabbing news, but shows that the lurching bureaucratic machine is slowly moving in the right direction.
For more on Health Canada and psychedelic access, check out Canada Amends Special Access to Psychedelics and Health Canada Approves First Special Access Request for Psilocybin
psilocybin psychedelic therapy psychotherapy health canada psychedelics-
Psychedelics1 week ago
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin5 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics4 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research